Jim GreenwoodBiotech Investors Should be Bullish: It’s a Long Road From a Tweet to a LawThe biopharmaceutical industry is under attack. It’s not the first time.Mar 23, 2017Mar 23, 2017
Jim GreenwoodTime Magazine’s “Report” On Drug Costs Littered With MisinformationA recent article in TIME Magazine by Brad Tuttle attempts to list “21 Incredibly Disturbing Facts About High Prescription Drug Prices,”…Jun 30, 2016Jun 30, 2016
Jim GreenwoodCongressional Patent Reform Threatens Medical InnovationThis week, executives from biotech companies around the country will be on Capitol Hill with an urgent message for lawmakers: a relatively…Sep 8, 2015Sep 8, 2015